Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project

Mossé, Yaël P.; Deyell, Rebecca J.; Berthold, Frank; Nagakawara, Akira; Ambros, Peter F.; Monclair, Tom; Cohn, Susan L.; Pearson, Andrew D.J.; London, Wendy B.; Matthay, Katherine K.

doi:10.1002/pbc.24777

Cited by 85 publications

(106 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1,2 Classification as high-risk or non-high-risk neuroblastoma depends on the stage defined by the International Neuroblastoma Staging System (INSS) 3,4 or less common the International Neuroblastoma Pathology Classification (INPC) proposed by Shimada et al 5,6 Over the past decades a multitude of prognosis and risk factors such as genetic mutations (e.g., deletion of chromosome 1p36, [7][8][9] altered expression of ALK, 10 PHOX2B) epigenetics, 9,11 ploidy 12 and age 13 have been identified. In the mid-1980s, the clinical and prognostic role of the proto-oncogene MYCN encoding for the protein N-Myc (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)) was first described.…”

Section: Introductionmentioning

confidence: 99%

Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma

Stanchi

Bruchelt

Handgretinger

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma

Stanchi

Bruchelt

Handgretinger

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…Furthermore, as many as 20% of patients with high-risk neuroblastoma experience disease progression during or have an inadequate response to induction therapy [4]. Tumor response rates are also lower in adolescents and adults, who often have indolent, chemoresistant tumors compared to tumors in younger children that tend to be more responsive to chemotherapy [66,67]. Although the specific induction regimens currently in use differ between different cooperative groups, most currently employed induction regimens for high-risk neuroblastoma utilize a combination of anthracyclines, platinum-containing compounds, alkylating agents and topoisomerase II inhibitors.…”

Section: Inductionmentioning

confidence: 99%

Overview and recent advances in the treatment of neuroblastoma

Whittle

Smith

Doherty

et al. 2017

Expert Review of Anticancer Therapy

311

258

View full text Add to dashboard Cite

Introduction: Children with neuroblastoma have widely divergent outcomes, ranging from cure in >90% of patients with low risk disease to <50% for those with high risk disease. Recent research has shed light on the biology of neuroblastoma, allowing for more accurate risk stratification and treatment reduction in many cases, although newer treatment strategies for children with high-risk and relapsed neuroblastoma are needed to improve outcomes. Areas covered: Neuroblastoma epidemiology, diagnosis, risk stratification, and recent advances in treatment of both newly diagnosed and relapsed neuroblastoma. Expert commentary: The identification of newer tumor targets and of novel cell-mediated immunotherapy agents may lead to novel therapeutic approaches, and clinical trials for regimens designed to target individual genetic aberrations in tumors are underway. A combination of therapeutic modalities will likely be required to improve survival and cure rates for patients with high-risk neuroblastoma.ARTICLE HISTORY

show abstract

“…Patients younger than 18 months of age have a much beter prognosis compared to the older patients [38,39], especially for patients between 12 and 18 months of age with biologically favorable disease. Older children, adolescents and young adults have a more indolent course and far worse outcomes [40].…”

Section: Iniltration Of Adjacent Organs/structuresmentioning

confidence: 99%

Neuroblastoma: The Clinical Aspects

Bhat¹,

McGregor²

2017

Neuroblastoma - Current State and Recent Updates

View full text Add to dashboard Cite

Neuroblastoma is a predominantly pediatric cancer, arising from the primordial neural crest cells that form the sympathetic nervous system. The prognosis for patients with neuroblastoma can vary from uniform survival in low risk patients to fatality in patients with high risk disease. This chapter gives a brief overview of the epidemiology, genetics, clinical presentation, diagnosis, and discussion of the various staging systems and risk classiications of neuroblastoma. We also briely describe our understanding of the conventional and novel treatment modalities available and their efects on the current prognosis of patients with neuroblastoma. The purpose of this chapter is to serve as a brief overview of the clinical aspects of neuroblastoma, to serve as a foundation of knowledge for scientists aspiring to develop new therapeutic modalities for this dreadful pediatric disease.

show abstract

Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project

Cited by 85 publications

References 25 publications

Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma

Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma

Overview and recent advances in the treatment of neuroblastoma

Neuroblastoma: The Clinical Aspects

Contact Info

Product

Resources

About